Terlipressin in hepatorenal syndrome

Annals of Pharmacotherapy

Volumn 45, Issue 3, 2011, Pages 380-387

  Mazur, Joseph E ^a   Cooper, Tanna B ^a   Dasta, Joseph F ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Hepatorenal syndrome; Terlipressin; Vasopressin

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; CIMETIDINE; CREATININE; FRESH FROZEN PLASMA; NORADRENALIN; OCTREOTIDE; PLACEBO; TERLIPRESSIN; VASOPRESSIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ARTICLE; BREAST SKIN ISCHEMIA; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYANOSIS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART INFARCTION; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; HYPERVOLEMIA; INTESTINE ISCHEMIA; INTRACRANIAL HYPERTENSION; KIDNEY FUNCTION; LIVEDO RETICULARIS; LIVER FAILURE; LOADING DRUG DOSE; LOW DRUG DOSE; MEDLINE; MESENTERY ISCHEMIA; META ANALYSIS; MORTALITY; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY ACIDOSIS; RESPIRATORY DISTRESS; SEPSIS; SIDE EFFECT; SKIN NECROSIS; SUDDEN DEATH; SYSTEMATIC REVIEW; URINE VOLUME; VASOCONSTRICTION;

ARGININE VASOPRESSIN; HEPATORENAL SYNDROME; HUMANS; LYPRESSIN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 79952651691     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P195     Document Type: Article

References (27)

1. Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004;59:993-1001. DOI 10.1111/j.1365-2044.03877.x (Pubitemid 39307237)
2. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006;40:2170-7. DOI 10.1345/aph.1H373 (Pubitemid 44954436)
3. Asfar P, Radermacher P, Calès P, Oberti F. The effects of vasopressin and its analogues on the liver and its disorders in the critically ill. Curr Opin Crit Care 2010;16:148-52. DOI 10.1097/MCC.Ob013e328335a35b
4. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-46. DOI 10.1016/j.jhep.2007.02.001 (Pubitemid 46529046)
5. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70. (Pubitemid 28484945)
6. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-6. DOI 10.1046/j.1440-1746. 2003.02934.x (Pubitemid 36349860)
7. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-8. DOI 10.1053/j.gastro.2008.02.014 (Pubitemid 351615358)
8. Martin-Llahi M, Pepin M, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-9. DOI 10.1053/j.gastrol.2008.02.024 (Pubitemid 351626950)
9. Mukhtar A, Salah M, Aboulfetouh F, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. Crit Care Med 2011 (in press). DOI 10.1097/CCM.0b013e3182120842
10. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006;24:935-44. DOI 10.111/j.1365-2036.2006.03086.x (Pubitemid 44326374)
11. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006;4:CD005162. DOI 10:1002/14651858.CD005162.pub2
12. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010;25:880-5. DOI 10.1111/j.1440-1746.2009. 06132.x
13. Dobre M, Demirjian S, Schgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol Epub 2010 Mar 20. DOI 10.1007/s11255-010-9725-8
14. Eisenman A, Armali Z, Enat R, Bankir L, Baruch Y. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. J Internal Med 1999;246:183-90. (Pubitemid 29378923)
15. Kiser TH, Fish DN, Obritsch MD, et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005:20:1813-20. DOI 10.1093/ndt/gfh930 (Pubitemid 41222593)
16. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblended, pilot study. J Hepatol 2007;47:499-505. DOI 10.1016/j.jhep.2007.04. 010 (Pubitemid 47331744)
17. Sharma P, Kumar A, Shrama BC, Sarin SK. An open-label pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type I hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-97. DOI 10.1111/j.1572-0241.2008.01828.x
18. Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008;53:830-5. DOI 10.1007/s10620-007-9919-9 (Pubitemid 351317073)
19. Kalil JR, Cerqueira LA, Barbosa DS, et al. Poor outcomes with treatment of hepatorenal syndrome type I with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature. Arq Gastroenterol 2009;46:214-8. DOI 10.1590/S0004-28032009000300014
20. Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to iv bolus administration. Gastroenterology 2009;137:1179-89. DOI 10.1053/j.gastro.2009.03.064
21. Megarbane H, Barete S, Khosrotehrani K, et al. Two observations raising questions about risk factors of cutaneous necrosis induced by terlipressin (Glypressin). Dermatology 2009;219:334-7. DOI 10.1159/000195676
22. Sen S, Mookerjee RP, Jalan R. Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome? Gastroenterology 2002;123:2161-2. DOI 10.1053/gast.2002.37303
23. Shawcross DL, Davies NA, Mookerjee RP, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 2004;39:471-5. DOI 10.1002/hep.20044 (Pubitemid 38222188)
24. Posada C, Feal C, Garcia-Cruz A, et al. Cutaneous necrosis secondary to terlipressin therapy. Acta Derm Vencreol 2009;89:434-5. DOI 10.2340.00015555- 0651
25. DiMicoli A, Bracci E, Mirici Cappa F, et al. Terlipressin infusion induces ischemia of breast skin in a cirrhotic patient with hepatorenal syndrome. Dig Liver Dis 2008;40:304-5. DOI 10.1016/j.did.2007.11.009
26. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type I HRS and beyond. Hepatology 2006;43:385-94. DOI 10.1002/hep.21094
27. Kiser TH, MacLaren R, Fish DN. Treatment of hepatorenal syndrome. Pharmacotherapy 2009;29:1196-121